Articles: sepsis.
-
Critical care medicine · Jan 2003
Randomized Controlled Trial Multicenter Study Clinical TrialImpact of oligon central venous catheters on catheter colonization and catheter-related bloodstream infection.
To evaluate a new antimicrobial treatment for central venous catheters in comparison with a traditional treatment, by assessing the catheter colonization and catheter-related bloodstream infection rates in two groups of patients. ⋯ Oligon treatment is effective in limiting the catheter colonization rate. Due to the limited amount of events, this study lacked the power to detect significant differences in terms of catheter-related bloodstream infection rate.
-
European cytokine network · Jan 2003
Randomized Controlled Trial Comparative Study Clinical TrialAnti-inflammatory response after infusion of p55 soluble tumor necrosis factor receptor fusion protein for severe sepsis.
To investigate the effects of Lenercept , a recombinant soluble TNF receptor p55 fused to an immunoglobulin heavy chain IgG1, on the balance of pro- and anti-inflammatory mediators in sepsis. ⋯ Lenercept -treated patients experienced a protracted TNF-alpha half-life, leading to higher total TNF-alpha levels throughout the study. However, the treatment had no effects on anti-inflammatory mediators. Therefore, peripheral inflammatory processes might not have been significantly modified by the treatment. This might account for the lack of efficacy this treatment in septic patients
-
Der Urologe. Ausg. A · Jan 2003
Randomized Controlled Trial Clinical Trial[Perioperative antibiotic prophylaxis in transperitoneal tumor nephrectomy: does it lower the rate of clinically significant postoperative infections?].
This monocentric prospective randomized study was designed to determine the efficacy of single-shot perioperative antibiotic prophylaxis with 1 g ceftriaxone i.v. in transperitoneal tumor nephrectomy. Eighty-three patients were randomized either into a prophylaxis or a control group: 39 patients received 1 g ceftriaxone i.v. 30 min preoperatively and 44 no study medication. Characteristics of the two groups showed no statistical differences. ⋯ Costs of antibiotic prophylaxis and/or treatment resulted in 23.60/30.10ZZZ;EUR per patient. Perioperative prophylaxis with 1 g ceftriaxone i.v. decreases postoperative infection rates. Although not all infections have to be treated with antibiotics, there are pharmacoeconomic advantages of such prophylaxis.
-
Critical care medicine · Jan 2003
Randomized Controlled Trial Multicenter Study Clinical TrialDrotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis.
To assess the effects of drotrecogin alfa (activated) therapy, a recombinant human activated protein C, across clinically relevant subpopulations in a randomized, phase 3, placebo-controlled study of patients with severe sepsis (recombinant human activated protein C worldwide evaluation in severe sepsis [PROWESS]). ⋯ The administration of drotrecogin alfa (activated) to patients with severe sepsis was associated with a significant survival benefit that tended to increase with higher baseline likelihood of death. Current data suggest that the increased risk of bleeding does not vary according to likelihood of death.
-
Critical care medicine · Jan 2003
Review Randomized Controlled Trial Clinical TrialDrotrecogin alfa (activated) (recombinant human activated protein C) for the treatment of severe sepsis.
To review the data supporting drotrecogin alfa (activated) for severe sepsis treatment. ⋯ Coagulopathy and systemic inflammation are almost universal in patients with severe sepsis. Treatment of this disorder with drotrecogin alfa (activated) directly addresses these derangements and substantially reduces morbidity and mortality rates with potential for bleeding during infusion as the only known risk.